NYSE · LLY
Eli Lilly and Company
$1,373.00+$84.70 (+6.57%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 2.51% below the high.
Loading market information…
OTC · AXRX · USD
Stock price
Quote as of Oct 28, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Amexdrug Corporation’s quoted price sits in the upper half of its reported 52-week range, 0.0% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE COMPANY BEHIND THE TICKER
Amexdrug Corporation, founded in 1963 and headquartered in Commerce, California, operates as a pharmaceutical and cosmeceutical enterprise. Primarily, the company, via its subsidiaries, distributes pharmaceutical products. Beyond this core function, Amexdrug is also deeply involved in the entire lifecycle of pharmaceutical drugs, cosmetics, and medical devices, from their research and development phases through manufacturing and ultimate sale. The company's operations are divided into two main divisions: Distribution and Health and Beauty Products. Its extensive distribution network encompasses a wide range of items, including prescription and over-the-counter medications, various non-drug products, and health and beauty essentials. Amexdrug also provides services in private manufacturing and labeling. Specific product lines manufactured and sold by the company, often under its Sponix brand, include facial and body creams, arthritic pain relief treatments, and hair and nail care products. These goods are supplied to a diverse clientele such as pharmacies, beauty salons, beauty supply outlets, and other retail establishments. Within the state of California, Amexdrug's distribution channels primarily target independent pharmacies, extending secondarily to smaller pharmacy chains, alternative care facilities, and various wholesalers and retailers. The company adopted the name Amexdrug Corporation in April 2000, changing from its previous identity as Harlyn Products, Inc., to reflect its strategic focus on pharmaceutical sales.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:17 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$1,373.00+$84.70 (+6.57%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 2.51% below the high.
CA$5.74+CA$0.03 (+0.53%)
Aurora Cannabis Inc.’s quoted price sits in the lower half of its reported 52-week range, 34.4% below the high.
HK$0.85-HK$0.04 (-3.95%)
Regent Pacific Group Limited’s quoted price sits in the lower half of its reported 52-week range, 30.33% below the high.
$0.18$0.00 (0.0%)
Procyon Corporation’s quoted price sits in the lower half of its reported 52-week range, 35.71% below the high.
$0.00$0.00 (0.0%)
Burzynski Research Institute, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.57% below the high.
$0.00$0.00 (0.0%)
Quick-Med Technologies, Inc.’s quoted price sits in the upper half of its reported 52-week range, 37.5% below the high.
$0.00$0.00 (0.0%)
Aeolus Pharmaceuticals, Inc.: Healthcare · Drug Manufacturers - Specialty & Generic.
$0.00$0.00 (0.0%)
Arno Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 50.0% below the high.
